ArticleEuropean journal of clinical pharmacology2014
Checklist for standardized reporting of drug-drug interaction management guidelines.
Article in European journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.BMJ open · 2016Pooled it
- Development of a Core Outcome Measurement Set for studies of community pharmacist-led medication reviews in older patients with multimorbidity and polypharmacy.International journal of clinical pharmacy · 2026Article
- How to manage the overwhelming amount of database-detected interactions? A focus group meeting study on the management of database-detected risks of drug interactions.European journal of hospital pharmacy : science and practice · 2026Article
- Polypharmacy, drug-drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS.Frontiers in pharmacology · 2025Article
- Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational Therapeutics.Drug safety · 2024Article
- A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions.Frontiers in pharmacology · 2024Article
- Quality Indicators of Pharmaceutical Care for Integrative Healthcare: A Scoping Review of Indicators Developed Using the Delphi Technique.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.Frontiers in pharmacology · 2020Article
- Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions.Journal of the Medical Library Association : JMLA · 2019Article
- Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis.Drug safety · 2018Article
- Recommendations for selecting drug-drug interactions for clinical decision support.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016Article
- Recommendations to improve the usability of drug-drug interaction clinical decision support alerts.Journal of the American Medical Informatics Association : JAMIA · 2015Review
- Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.Drug safety · 2015Article
- Understanding and preventing drug-drug and drug-gene interactions.Expert review of clinical pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare providers in clinical practice.
methodsWe carried out a two-round Delphi process with an international panel of healthcare providers, most of whom are pharmacists involved in providing DDI information, in order to select those items that should be addressed in DDI management guidelines (including grading systems that could be used).
resultsTwenty-three panellists reached consensus on 19 items in two main domains. These were consolidated into a checklist of 15 elements for standardized reporting in management guidelines. For each element a description is provided to specify what information should be documented in that specific element.
conclusionsIt was possible to reach a broad consensus on which relevant items should be included in a checklist for the development of DDI management guidelines.
Indexed as
Identifiers
24306496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.